Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23241377)

1.

Emergence of a novel extended-spectrum-β-lactamase (ESBL)-producing, fluoroquinolone-resistant clone of extraintestinal pathogenic Escherichia coli in Kumasi, Ghana.

Feglo P, Adu-Sarkodie Y, Ayisi L, Jain R, Spurbeck RR, Springman AC, Engleberg NC, Newton DW, Xi C, Walk ST.

J Clin Microbiol. 2013 Feb;51(2):728-30. doi: 10.1128/JCM.03006-12. Epub 2012 Dec 12. No abstract available.

2.

Genetic background of Escherichia coli and extended-spectrum beta-lactamase type.

Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, Gouriou S, Picard B, Denamur E.

Emerg Infect Dis. 2005 Jan;11(1):54-61.

3.

Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan.

Matsumura Y, Yamamoto M, Higuchi T, Komori T, Tsuboi F, Hayashi A, Sugimoto Y, Hotta G, Matsushima A, Nagao M, Takakura S, Ichiyama S.

Int J Antimicrob Agents. 2012 Aug;40(2):158-62. doi: 10.1016/j.ijantimicag.2012.04.013. Epub 2012 Jun 27.

PMID:
22743014
5.

Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.

Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, Mensa J.

J Antimicrob Chemother. 2009 Mar;63(3):568-74. doi: 10.1093/jac/dkn514. Epub 2009 Jan 6.

6.

Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO.

Clin Infect Dis. 2001 Oct 15;33(8):1288-94. Epub 2001 Sep 14.

7.

The revolving door between hospital and community: extended-spectrum beta-lactamase-producing Escherichia coli in Dublin.

Burke L, Humphreys H, Fitzgerald-Hughes D.

J Hosp Infect. 2012 Jul;81(3):192-8. doi: 10.1016/j.jhin.2012.04.021. Epub 2012 Jun 2.

PMID:
22658893
8.

Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.

Yokota S, Sato T, Okubo T, Ohkoshi Y, Okabayashi T, Kuwahara O, Tamura Y, Fujii N.

Chemotherapy. 2012;58(1):52-9. doi: 10.1159/000336129. Epub 2012 Feb 15.

PMID:
22343392
9.

Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.

Sorlozano A, Gutierrez J, Jimenez A, de Dios Luna J, Martínez JL.

J Clin Microbiol. 2007 Aug;45(8):2740-2. Epub 2007 Jun 13.

10.

Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water.

Dhanji H, Murphy NM, Akhigbe C, Doumith M, Hope R, Livermore DM, Woodford N.

J Antimicrob Chemother. 2011 Mar;66(3):512-6. doi: 10.1093/jac/dkq472. Epub 2010 Dec 15.

11.

Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States.

Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV.

Chemotherapy. 2011;57(4):335-8. doi: 10.1159/000329661. Epub 2011 Sep 6.

PMID:
21912115
12.

Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment.

Pitout JD.

Expert Rev Anti Infect Ther. 2012 Oct;10(10):1165-76. doi: 10.1586/eri.12.110. Review.

PMID:
23199402
13.

Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.

Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2008 May;52(5):1846-9. doi: 10.1128/AAC.01176-07. Epub 2008 Feb 25.

14.

Characteristics of Romanian fluoroquinolone-resistant human clinical Escherichia coli isolates.

Usein CR, Tatu-Chiţoiu D, Nica M, Ciontea SA, Palade AM, Condei M, Damian M.

Roum Arch Microbiol Immunol. 2008 Jan-Jun;67(1-2):23-9.

PMID:
19284163
15.

Multi-drug resistant escherichia coli with extended-spectrum beta-lactamase activity and fluoroquinolone resistance isolated from clinical infections in dogs.

Warren A, Townsend K, King T, Moss S, O'Boyle D, Yates R, Trott DJ.

Aust Vet J. 2001 Sep;79(9):621-3. Review. No abstract available.

PMID:
11702934
16.

Fluoroquinolone resistance in pediatric bloodstream infections because of Escherichia coli and Klebsiella species.

Kim JY, Lautenbach E, Chu J, Goyal M, Nachamkin I, McGowan K, Coffin S, Zaoutis T.

Am J Infect Control. 2008 Feb;36(1):70-3. doi: 10.1016/j.ajic.2007.01.012.

PMID:
18241740
17.

Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.

Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, Lázaro E, de Abajo FJ, Campos J; Spanish ESBL-EARS-Net Study Group.

J Antimicrob Chemother. 2010 Nov;65(11):2459-63. doi: 10.1093/jac/dkq346. Epub 2010 Sep 16.

18.

Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M.

Clin Infect Dis. 2010 Aug 1;51(3):286-94. doi: 10.1086/653932.

19.

Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.

Tsui K, Wong SS, Lin LC, Tsai CR, Chen LC, Huang CH.

J Microbiol Immunol Infect. 2012 Jun;45(3):193-9. doi: 10.1016/j.jmii.2011.11.003. Epub 2012 May 12.

PMID:
22580086
20.

Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, Leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM.

J Antimicrob Chemother. 2004 Oct;54(4):735-43. Epub 2004 Sep 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk